About N-alpha-acetyltransferase 35, NatC auxiliary subunit
N-alpha-acetyltransferase 35, NatC auxiliary subunit (NAA35) is a protein
from Homo sapiens identified by UniProt accession
Q5VZE5, 725 residues long.
MolForge cross-references it against 0 known binders and
18 disease associations.
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
Disease associations (18)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- atopic eczema · score 0.14
- esophageal squamous cell carcinoma · score 0.05
- hypoparathyroidism, familial isolated, 2 · score 0.05
- pseudohypoparathyroidism type 2 · score 0.04
- Familial isolated hypoparathyroidism · score 0.03
- pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 9 · score 0.03
- cancer · score 0.02
- viral load · score 0.02
- neoplasm · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Experimental structures are not indexed in MolForge yet —
search RCSB PDB for Q5VZE5.
Amino-acid sequence (725 residues)
MVMKASVDDD DSGWELSMPE KMEKSNTNWV DITQDFEEAC RELKLGELLH DKLFGLFEAM SAIEMMDPKM DAGMIGNQVN RKVLNFEQAI KDGTIKIKDL TLPELIGIMD TCFCCLITWL EGHSLAQTVF TCLYIHNPDF IEDPAMKAFA LGILKICDIA REKVNKAAVF EEEDFQSMTY GFKMANSVTD LRVTGMLKDV EDDMQRRVKS TRSRQGEERD PEVELEHQQC LAVFSRVKFT RVLLTVLIAF TKKETSAVAE AQKLMVQAAD LLSAIHNSLH HGIQAQNDTT KGDHPIMMGF EPLVNQRLLP PTFPRYAKII KREEMVNYFA RLIDRIKTVC EVVNLTNLHC ILDFFCEFSE QSPCVLSRSL LQTTFLVDNK KVFGTHLMQD MVKDALRSFV SPPVLSPKCY LYNNHQAKDC IDSFVTHCVR PFCSLIQIHG HNRARQRDKL GHILEEFATL QDEAEKVDAA LHTMLLKQEP QRQHLACLGT WVLYHNLRIM IQYLLSGFEL ELYSMHEYYY IYWYLSEFLY AWLMSTLSRA DGSQMAEERI MEEQQKGRSS KKTKKKKKVR PLSREITMSQ AYQNMCAGMF KTMVAFDMDG KVRKPKFELD SEQVRYEHRF APFNSVMTPP PVHYLQFKEM SDLNKYSPPP QSPELYVAAS KHFQQAKMIL ENIPNPDHEV NRILKVAKPN FVVMKLLAGG HKKESKVPPE FDFSAHKYFP VVKLV
Explore N-alpha-acetyltransferase 35, NatC auxiliary subunit with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets